Article ID Journal Published Year Pages File Type
5963700 International Journal of Cardiology 2016 8 Pages PDF
Abstract

BackgroundStress echo (SE) may have a role in the outcome in patients with hypertrophic cardiomyopathy (HCM).ObjectivesThe aim was to assess the prognostic value of SE in a retrospective multicenter study in HCM.MethodsWe enrolled 706 HCM patients. The employed stress was exercise (n = 608) and/or vasodilator (n = 146, dipyridamole in 98 and adenosine in 48). We defined SE positivity according to clinical/hemodynamic criteria including: symptoms (all stress modalities), exercise-induced hypotension (failure to increase or fall > 20 mm Hg, exercise) and exercise-induced left ventricular outflow tract obstruction (left ventricular outflow tract obstruction > 50 mm Hg); and ischemic criteria, such as new wall motion abnormalities (new wall motion abnormality) and/or reduction of coronary flow reserve velocity (CFVR ≤ 2.0) on left anterior descending coronary artery with vasodilator stress assessed in 116 patients. All patients completed the clinical follow-up.ResultsPositive SE showed more frequently CFVR reduction, exercise-induced hypotension, left ventricular outflow tract obstruction, and symptoms (38, 23, 20 and 15% respectively), but new wall motion abnormality only in 6%. During a median follow-up of 49 months 180 events were observed, including 40 deaths. Clinical/hemodynamic criteria did not predict outcome (X2 0.599, p = 0.598), whereas ischemia-related SE criteria (X2: 111.120, p < 0.0001) was significantly related to outcome. Similarly, mortality was predicted with SE ischemic-criteria (X2 16.645, p < 0.0001).ConclusionsSE has an important prognostic significance in HCM patients, with ischemia-related end-points showing greater predictive accuracy than hemodynamic endpoints. New wall motion abnormalities and impairment of CFVR should be specifically included in SE protocols for HCM.

Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Authors
, , , , , , , , , , , , , , , ,